| Literature DB >> 28503918 |
Lingfeng Chen1,2, Yiyi Jin1, Weitao Fu1, Siyang Xiao1, Chen Feng1, Bo Fang1, Yugui Gu3, Chenglong Li1, Yunjie Zhao1, Zhiguo Liu1, Guang Liang1,2.
Abstract
Acute lung injury (ALI) has a high lethality rate, and interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) contribute most to tissue deterioration in cases of ALI. In this study, we designed and synthesized a new series of thiazolo[3,2-a]pyrimidine derivatives based on a previously identified lead compound, and we evaluated their anti-inflammatory activities. Structure-activity relationship studies led to the discovery of two highly potent inhibitors. The two promising compounds were found to inhibit lipopolysaccharide (LPS)-induced IL-6 and TNF-α release in a dose-dependent manner in mouse primary peritoneal macrophages (MPMs). Furthermore, administration of these compounds resulted in lung histopathological improvements and attenuated LPS-induced ALI in vivo. Taken together, these data indicate that these novel thiazolo[3,2-a]pyrimidine derivatives could be developed as candidate drugs for the treatment of ALI.Entities:
Keywords: acute lung injury; anti-inflammatory; cytokines; interleukins; thiazolo[3,2-a]pyrimidines
Mesh:
Substances:
Year: 2017 PMID: 28503918 DOI: 10.1002/cmdc.201700175
Source DB: PubMed Journal: ChemMedChem ISSN: 1860-7179 Impact factor: 3.466